Hedge fund Lynx1 Capital Management LP has disclosed a new activist stake of over 5% in Passage BIO, Inc. ($PASG). The filing, a Schedule 13D, was submitted to the Securities and Exchange Commission (SEC) on July 2, 2026. A 13D filing, unlike a 13G, indicates an intention to influence the management or policies of the company.

Lynx1 Capital Management is a hedge fund that makes strategic investments, and an activist stake in a clinical-stage biotechnology company like Passage BIO may signal a belief in untapped potential or a desire to drive changes that will accelerate the development of its genetic medicines. Activist funds often identify companies they believe are undervalued or have potential for operational improvements.

For individual traders, a 13D filing is an interesting signal, indicating that a significant stakeholder intends to be actively involved in the company. However, it is important to remember that activist intentions are not a guarantee of success, and outcomes depend heavily on strategy implementation and cooperation with management. These filings reflect holdings at the time of submission and do not necessarily predict future stock performance.